PAOG Engages Veristat For CRO Services To Advance CBD COPD Treatment
January 05 2021 - 8:23AM
InvestorsHub Cannabis NewsWire
Sandusky, OH -- January 5, 2021 --
InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today announced an engagement
with Veristat, Inc., a contract research organization headquartered
in Southborough Massachusetts. PAOG has engaged Veristat to
assist in advancing PAOG with its proprietary Cannabidiol (CBD)
extract for the treatment of Chronic Obstructive Pulmonary Disorder
(COPD) toward initiating an
Investigational New Drug application (IND) with the Food and Drug
Administration (FDA).
On July 30,
2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink:
KALY) RespRx is a cannabis treatment under development for COPD
derived from a patented cannabis extraction method - U.S. Patent
No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING
HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS
PLANT."
Veristat, a scientific-minded global
clinical research organization (CRO), enables sponsors to solve the
unique and complex challenges associated with accelerating
therapies through clinical
development to regulatory
approval.
With more than 26 years' experience in clinical trial planning and
execution, Veristat is equipped to support any development
program.
Learn more about
PAOG at www.paogroupinc.com.
Learn more about Veristat at
www.veristat.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about PAO Group Inc (PK) (OTCMarkets): 0 recent articles
More PAO Group Inc (PK) News Articles